Fourpath Capital Management LLC Purchases 306 Shares of Novo Nordisk A/S (NYSE:NVO)

Fourpath Capital Management LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 10.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,306 shares of the company’s stock after acquiring an additional 306 shares during the period. Fourpath Capital Management LLC’s holdings in Novo Nordisk A/S were worth $284,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in NVO. Optas LLC boosted its stake in Novo Nordisk A/S by 10.9% in the fourth quarter. Optas LLC now owns 6,259 shares of the company’s stock valued at $538,000 after buying an additional 614 shares in the last quarter. Financial Life Planners bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $51,000. Brentview Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $201,000. Catalina Capital Group LLC increased its position in Novo Nordisk A/S by 17.5% during the 4th quarter. Catalina Capital Group LLC now owns 4,264 shares of the company’s stock worth $367,000 after purchasing an additional 634 shares in the last quarter. Finally, Princeton Global Asset Management LLC lifted its stake in Novo Nordisk A/S by 56.1% in the 4th quarter. Princeton Global Asset Management LLC now owns 2,781 shares of the company’s stock valued at $239,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $82.60 on Wednesday. The stock has a market capitalization of $370.65 billion, a PE ratio of 26.73, a PEG ratio of 0.93 and a beta of 0.45. The business’s 50 day simple moving average is $93.12 and its 200 day simple moving average is $112.54. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.